Lasmiditan Succinate Tablet shortage
Lasmiditan Succinate Tablet is currently listed in shortage by the FDA. The FDA lists 6 affected products. This page was last refreshed from FDA data on Sep 23, 2026.
Eli Lilly is stopping Reyvow (lasmiditan succinate) tablets in both the 50 mg and 100 mg strengths, and this change is permanent. Distribution ends May 31, 2026, and no other manufacturer of this medicine is currently listed as a supply source.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available.
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Lasmiditan Succinate Tablet. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Nov 3, 2025Currently in shortage6 of 6 products affected.
-
Nov 3, 2025First reported to the FDA6 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Eli Lilly and Co. 📞 800-545-5979 6 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Reyvow, Tablet, 100 mg (NDC 0002-4491-61) | — | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — |
| To Be Discontinued | Reyvow, Tablet, 100 mg (NDC 0002-4491-08) | — | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — |
| To Be Discontinued | Reyvow, Tablet, 50 mg (NDC 0002-4312-62) | — | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — |
| To Be Discontinued | Reyvow, Tablet, 50 mg (NDC 0002-4312-08) | — | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — |
| To Be Discontinued | Reyvow, Tablet, 50 mg (NDC 0002-4312-61) | — | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — |
| To Be Discontinued | Reyvow, Tablet, 100 mg (NDC 0002-4491-62) | — | — | A business decision was made to discontinue manufacture of the 50 mg and 100 mg tablets. Distribution will end on May 31, 2026. | — |
These rows are manufacturer reports to the FDA for Lasmiditan Succinate Tablet — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Lasmiditan Succinate Tablet? options further down this page.
Why is Lasmiditan Succinate Tablet in shortage?
Eli Lilly has made a business decision to permanently stop making Reyvow (lasmiditan) in both the 50 mg and 100 mg tablet strengths. This isn't due to a safety issue or manufacturing problem — it's simply a company business choice. Distribution of all Reyvow tablets will end on May 31, 2026, so whatever supply exists will stop being shipped out after that date.
It's worth knowing that the FDA did not provide a more specific public reason beyond it being a business decision by Eli Lilly. This report covers only Eli Lilly's products, so it speaks only to their version of this medication.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Lasmiditan Succinate Tablet, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Lasmiditan Succinate Tablet?
Lasmiditan (brand name Reyvow) is currently on the FDA shortage list, so I want to walk you through what that means for you.
Both available strengths are affected. Neither the 50 mg nor the 100 mg tablet has an available source right now, so this applies no matter which one you take.
The reason listed here is a business decision by the manufacturer, Eli Lilly, to discontinue making both the 50 mg and 100 mg tablets. According to the report, distribution will end on May 31, 2026. This is only the maker on this shortage record; still, because it is a discontinuation rather than a temporary delay, this supply problem may be lasting. That makes a conversation with your prescriber the right next step to plan ahead.
Here is what I suggest, in order:
- Do not stop, skip, or change your dose on your own.
- Ask your pharmacy to check wholesalers, since local stock can differ from national reports.
- Because this medicine is being discontinued, talk with your prescriber or pharmacist about a clinician-chosen option that fits you.
- Manufacturer contact numbers are listed on this page for reference, though pharmacies usually handle those calls.
This is general, manufacturer-reported information and may not match your local pharmacy's actual stock, so please lean on your care team for advice that fits you.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
- This is a controlled substance. Transfers between pharmacies and switching strengths have extra federal/state rules — ask the pharmacy before you assume a transfer is possible.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Therapeutic equivalents & pricing 3 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Reyvow 100 mg | Eli | 8 tablets | $88.772 | — | Availability likely |
| Reyvow 100 mg | Eli | 4 tablets | — | — | Discontinued |
| Reyvow 50 mg | Eli | 2 tablets | — | — | Discontinued |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Lasmiditan Succinate Tablet — that fall in the same broad treatment class (antimigraine preparations) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other neurology shortages
Lasmiditan Succinate Tablet shortage FAQs
Is Lasmiditan Succinate Tablet in shortage?
Which products are affected?
When will Lasmiditan Succinate Tablet be available again?
What should I do if I take Lasmiditan Succinate Tablet?
Still have a question about the Lasmiditan Succinate Tablet shortage?
Ask a pharmacist about this shortage →View Lasmiditan Succinate Tablet on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.